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Dramatic changes in global HIV and AIDS
estimates were publicised at the end of 2007,
1 with
a notable downward adjustment in the estimated
number of people living with HIV (PLHIV) from
39.5 million (range 34.1–47.1 million) published in
2006
2 to 33.2 million (range 30.6–36.1 million).
1
Both the original and revised estimates are by any
measure catastrophic; however, the new lower
estimates come at a time when global disease
burden estimates are under intense scrutiny.
34
While the 2007 AIDS Epidemic Update report
noted that the downward adjustments were the
result of better data leading to changes in assump-
tions and thereby estimates, we recognise the need
for the highest level of transparency and opportu-
nity for scientific critique. Since 2004 we have
provided detailed descriptions of the tools and
assumptions used in generating HIV and AIDS
estimates, as well as the data and analyses under-
pinning these assumptions.
5–7 This current supple-
ment assembles important new data relating to
several assumptions used for the new HIV and
AIDS estimates. By bringing together a new
collection of methodological papers in this supple-
ment, we aim to provide easy access to the
scientific basis underlying the latest HIV and
AIDS estimates for 2007.
189
The process of synthesising new data, reviewing
assumptions and providing guidance on methods is
driven by the UNAIDS Reference Group on
Estimates, Modelling and Projections.
10 This group,
which was established in 1999 and is made up of
academics, researchers and public health practi-
tioners, has led the development of several model-
ling and estimation packages (for example, the
Workbook, EPP and the AIM module in Spectrum)
that are used by countries and UNAIDS and the
World Health Organization in preparing national
estimates. The group meets yearly to review the
major themes providing inputs to the estimation
process and it is this process that has stimulated
many of the papers in this supplement.
Based on the recommendations of the Reference
Group, UNAIDS and WHO, along with other
partners, hold workshops for national epidemiolo-
gists who are trained on the new methods and
assumptions and the new versions of the modelling
and estimation software. These workshops are
held every two years and ensure that national
epidemiologists have access to the most recent
recommendations of the Reference Group and are
trained in the use of the new tools. This process
ensures that estimates made for different countries
are comparable, as common assumptions, defini-
tions and procedures have been used, although the
accuracy of estimates across countries will vary
owing to differences in data availability and the
level of the epidemic.
Several papers in this supplement synthesise the
data from multiple sources that have led to recent
changes in assumptions behind the global HIV
estimates. For example, one major adjustment is in
the calibration of HIV prevalence measured at
antenatal clinics (ANC) in countries with general-
ised epidemics, based on a comparison of HIV
prevalence from ANC to national population-based
surveys,
11–13 which has reduced the overall estimate
of the number of people living with HIV. A further
change, which has lowered the historical estimate
of incidence generating the current prevalence, is
based on the longer survival of PLHIV.
14–16 In
combination with the national household-based
survey in India from 2006, which prompted the
country to lower its estimate of national HIV
prevalence,
17 these changes have resulted in drastic
reductions in estimates of PLHIV, new HIV
infections and AIDS mortality.
1 In contrast,
another important change relates to the quantifi-
cation of the number of people eligible for
antiretroviral therapy (ART). With the overall
longer survival,
14–16 and the data and analyses
leading to the adoption of a longer assumed period
from seroconversion to ART eligibility and from
ART eligibility to death,
14 18 estimates of the
number of people in need of ART have been
revised and, as of the end of 2007, stand at 9.7
million (range 8.7–11 million) for low-income and
middle-income countries
8 compared to the previous
estimate for 2006 of 7.1 million (6–8.4 million).
19
The eART-linc collaboration writing group,
comprising Wandel and colleagues,
18 presents an
individual participant data meta-analysis of the
time from seroconversion to ART eligibility and
from ART eligibility to death in the absence of
ART. Unfortunately it was not possible with the
available data to estimate these times for the full
WHO criteria (CD4 ,200 cells 610
6/l, or WHO
stage 4, or 200, CD4 cells 610
6/l ,350 and WHO
stage 3).
20 The time from seroconversion to ART
eligibility is estimated at 66% and 48% of the total
survival time for eligibility criteria CD4 ,200 cells
610
6/l and CD4 ,275 cells 610
6/l, respectively.
This supports the implementation in Spectrum of
the time from seroconversion to ART eligibility as
a distribution with a median of 8 years out of 11
years total survival for most countries and 6.5 years
out of 9 years for countries where HIV subtype E is
dominant.
14 These new parameter estimates for
ART needs among adults are substantiated by
independent analyses of a cohort in Masaka,
Uganda, suggesting a 35-month period from ART
eligibility to death (in the absence of ART), based
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21 Two published studies with a
community-based assessment of the prevalence of the need for
ART in adults allow for validation of the new parameter
estimates. Applying the new Spectrum methods and assump-
tions to Malawi yields 31% (range 26%–35%) of adult PLHIV
(.15 years) who are eligible for ART in 2006, while the
empirical estimates for the same year in Karonga district were
38% for the Malawi national programme criteria (CD4 ,250
cells 610
6/l or WHO stage 3/4), 34% for the full WHO criteria
and 29% for CD4 ,200 cells 610
6/l as the criterion among 18–
59 year olds.
22 Applying the new Spectrum methods and
assumptions to South Africa yields 14% (range 13%–16%) and
17% (range 15%–18%) of 15–49-year-old PLHIV who were
eligible for ART in 2001 and 2002, respectively, while the
empirical estimate was 9.5% (95% CI 6.1% to 14.9%) among 15–
49-year-olds in early 2002 in a township near Johannesberg for
the CD4 ,200 cells 610
6/l criterion only
23—the proportion
corresponding to the full WHO criteria is expected to be
somewhat larger. Therefore, the new assumptions seem to
provide reasonable results, and should be preferred over the
previous set of assumptions.
24
Given the past revisions in global HIV estimates and our
increasing emphasis on the range of plausible estimates, we
recognise the increasing need for improved and more realistic
uncertainty bounds. Building on previous methods for deriving
uncertainty bounds around the HIV and AIDS estimates, a new
Bayesian approach that makes full use of the empirical data for
each country is implemented in the latest version of the
Estimation and Projection Package (EPP).
12 13 This is comple-
mented by use of Monte Carlo methods in Spectrum for the
uncertainty around HIV prevalence in concentrated epidemics,
and around all other indicators for both types of epidemics.
14
This supplement includes an illustrative example in which
some of the methods described here have been applied to data
from Ukraine.
25 It should be noted that the Ukraine estimate
may be on the high side, given the strong assumptions for the
sexual partners of the people in the groups at higher risk,
resulting in these partners representing almost a third of all
people living with HIV. Also included are papers that synthesise
estimates for special populations that are often missing or not
distinguished in national and international estimates. For
example, the global estimates resulting from the implementa-
tion of the methods described in other papers in this
supplement have been combined with estimates of populations
affected by emergencies in order to estimate the AIDS burden
among people affected by emergencies.
26 An example of a paper
that fills a gap in the global estimates is the literature review by
Caceres et al
27 on the epidemiology of male same-sex behaviour
in low and middle-income countries.
The discrepancies between estimates of the prevalence of
maternal orphanhood between UN demographic models and
demographic and health surveys (DHS) are investigated using
analyses of data from Manicaland, Zimbabwe.
28 The authors
offer as a possible explanation for this discrepancy—the
misreporting of foster parents as natural parents, which appears
to be particularly common among foster mothers.
Two papers investigate the possible bias in HIV seropreva-
lence estimates from national household surveys.
29 30 Mishra et
al, reporting from the institution that has provided technical
assistance to the DHS, analysed 14 surveys and confirm their
earlier finding on the basis of eight surveys that national surveys
are not much affected by non-response bias.
31 An independent
analysis by Marston et al
30 specifically investigated the role of
mobility. Of nine national surveys examined, the bias due to
non-response amounted to only 10% in the most severe case and
in no case was the difference in observed versus adjusted HIV
prevalence statistically significant, similar to the findings of
Mishra et al.
29 Still, it should be noted that the analytical
approach is limited because of the lack of specific risk
information about people who are eligible for participation in
the survey but who were absent or did not give an interview
for another reason. Mishra et al
29 also investigate the potential
for bias in surveys in countries with concentrated epidemics,
specifically related to the exclusion of populations that are
at higher risk of HIV infection from the sampling frame of
the survey. They conclude that bias is unlikely to result in
large differences in national prevalence—for example, in
the most extreme scenario the adult HIV prevalence increased
from 0.28% to 0.35% in India, and from 0.6% to 1% in
Cambodia.
Two papers compare HIV prevalence estimates from ANC
surveillance to population-based surveys. A first analysis was
conducted for urban and rural areas for 26 countries, and
concluded that adult prevalence in the surveys was approxi-
mately 0.8 of the ANC prevalence.
11 A second analysis confirms
this association, but shows that the prevalence in ANC is
similar to the prevalence found in the clusters of the surveys
that are near ANC, both for adults and for women.
32 Together,
these papers suggest that, besides differences in prevalence by
gender, the major reason for the prevalence difference between
surveys and ANC is because of the geographical non-representa-
tiveness of ANC sites included in countries’ surveillance
systems, with urban ANC sites disproportionately located in
the larger cities and towns, and similarly rural ANC sites leaving
out the remote areas of countries that are poorly covered by
antenatal services. The papers also provide the rationale for the
recalibration of ANC prevalence by a factor of approximately
0.8 when making estimates of national HIV prevalence in
countries without specific, local data based on the consistency
of findings, as implemented in EPP.
12 13
In addition to making national estimates every two years,
UNAIDS and WHO also do a systematic review of the quality
of data available in countries to make their estimates of HIV
and AIDS. The quality of sero-surveillance in low-income and
middle-income countries is reviewed through 2007.
33
Surprisingly, there is little evidence on a general trend in
improved surveillance systems among the 127 country systems
that were reviewed. Overall, 44 out of 127 countries were scored
as poorly functioning systems, a number similar to that found
two years earlier.
34 However, some countries have strengthened
their systems and data availability. The improvement that has
occurred is primarily in countries with data from nationally
representative surveys which test for HIV, mainly in sub-
Saharan Africa.
Heaton et al
35 present and discuss the potential and the
difficulties of various modelling approaches to estimate the
number of HIV infections averted by prevention programmes.
This is an important question to address as governments and
other organisations would like to know if the money and efforts
spent on prevention have yielded tangible benefits. The authors
of the paper argue that while all approaches have strengths and
weaknesses, a disease-modelling approach will yield the best
results and can be used to estimate infections averted.
In reviewing the estimates of HIV prevalence and the
associated estimates of impact it is important to remember
their function and not solely concentrate on getting the
headline figure right. Key functions of the estimates are to plan
for the impact of the infection and disease; to plan resource
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care and to understand trends in the epidemic. In revising
assumptions and current estimates it is important to similarly
revise historical estimates so that the trends can be explored in a
consistent manner. This is built into the models used to explore
the epidemiological data. However, future changes in the
epidemiology of infection and biases in surveillance data
brought about by increased testing and increased availability
of treatment will have to be considered. Despite the large
number of people currently being treated, the impact of
treatment on estimates has to date been limited because it
takes time for the impact of improved survival to accumulate.
However, this situation is likely to change over the next two
years and the methods will need to be adjusted accordingly. In
addition to an increased HIV prevalence because of improved
survival rather than more new infections we can expect some
changes in behaviour, both risk behaviour and contact with
services, brought about by high HIV testing and knowledge of
serostatus.
For planning purposes we would ideally like to understand
the current pattern of spread of HIV and be able to evaluate the
effectiveness of prevention programmes in the short term.
Unfortunately, tools to measure recent incidence beyond a
limited research setting are not currently available. HIV
incidence estimates, as currently calculated in a model based
on HIV prevalence trends,
14 are likely to be reasonably precise
for the period up to several years ago but become much less
reliable for recent and current years. While a method has been
developed to derive incidence from age-specific prevalence
measured in national surveys,
36 direct measurement of incidence
remains highly desirable, although there are important chal-
lenges that need to be overcome.
37 38 This extends beyond a
technological problem since the required sample sizes, especially
in low prevalence settings, to understand incidence would be
very large.
Estimates for generalised epidemics are now much more
precise than those for concentrated epidemics, where there is
much uncertainty around the size of specific groups, and the
representativeness of HIV sentinel surveillance among these
groups. A number of methods to estimate the size of these
groups are available, but they can be demanding in terms of
required data and analytical capacity. There is currently no
consensus on the best and most appropriate methods which
means rigour is often compromised when deciding on which
estimates to use. These difficulties in assessing the current state
of the epidemic in low prevalence situations also undermine
attempts to compare prevalence estimates over time and
understand the trends in the epidemic in these locations.
These problems have been less of a focus in this supplement
because of the dramatic changes in estimates for generalised
epidemics and their dominance in the estimates. None the less,
in planning prevention, treatment and care, understanding the
situation in concentrated and low-level epidemics is important
and more work is required in this area.
In conclusion, we anticipate that further improved data,
along with changes in HIV prevention and care, will cause
future changes in both assumptions and the estimates derived
from them. As we hope we have illustrated in this supplement,
we are committed to further improve estimates and to continue
to provide the scientific community, policy-makers and the
wider public with the opportunity to carefully examine the
evidence behind this work.
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